Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement

Jurisic, G, Sundberg, JP and Detmar, M (2013) Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. Inflammatory Bowel Diseases. pp. 1983-1989.


Background: In contrast to the prominent function of the blood vasculature in promoting tissue inflammation, the role of lymphatic vessels in inflammation has been scarcely studied in vivo. To investigate whether modulating lymphatic vessel function might affect the course of chronic inflammation, the major lymphangiogenic receptor, vascular growth factor receptor 3 (VEGFR-3, FLT4), was blocked in an established model of inflammatory bowel disease. Methods: Interleukin 10 (IL10)-deficient mice that spontaneously develop inflammatory bowel disease were treated with a blocking antibody to VEGFR-3 for 18 days, and the inflammatory changes in colon tissue and the blood and lymphatic vascularization were quantitatively analyzed. Results: We found a significant increase in the severity of colon inflammation in anti-VEGFR-3-treated mice. This was accompanied by an increased number of enlarged and tortuous lymphatic vessels and edema in colon submucosa, indicating impaired lymphatic function. In contrast, no major effects of the treatment on the blood vasculature were observed. Conclusions: These results indicate that therapies aimed at promoting lymphatic function, e.g., with prolymphangiogenic factors, such as VEGF-C, might provide a novel strategy for the treatment of inflammatory conditions, such as inflammatory bowel disease. Copyright 2013 Crohn's & Colitis Foundation of America, Inc

Item Type: Article
Additional Information: pubid: 32 nvp_institute: NIBR contributor_address: (Jurisic, Detmar) Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Wolfgang-Pauli-Str. 10, HCI H303, CH-8093 Zurich, Switzerland (Sundberg) Jackson Laboratory, Bar Harbor, ME, United States (Jurisic) Novartis Institutes for Biomedical Research, Forum 1 Novartis Campus, Basel, Switzerland
Date Deposited: 13 Oct 2015 13:13
Last Modified: 13 Oct 2015 13:13


Email Alerts

Register with OAK to receive email alerts for saved searches.